Skip to main content
Premium Trial:

Request an Annual Quote

Inverness Gives Biosite Revised Commitment Letters From 'Proposed Financing Sources'

NEW YORK (GenomeWeb News) — Biosite said today that Inverness Medical Innovations has given the company a set of revised commitment letters from Inverness' “proposed financing sources” that will likely pay for its unsolicited bid to acquire Biosite for $90 a share. 
Biosite said it will file these revisions with the US Securities and Exchange Commission, but those changes are not yet available on the SEC’s website.
Biosite’s board has not withdrawn or changed its recommendations concerning its agreement to be acquired by Beckman Coulter for $85 a share.
The company said that offer will expire on April 27 unless Beckman extends it, but for now that agreement “remains in effect.”
Beckman said yesterday the Federal Trade Commission cleared its merger with Biosite.
Beckman CEO Scott Garrett said two weeks ago the Inverness offer was shakier than Beckman’s because he doubted Inverness could land the financing it would need to swing the deal on such short notice.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.